Revenue Breakdown
Composition ()
No data
Revenue Streams
Bristol-Myers Squibb Co (BMY) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Eliquis, accounting for 30.6% of total sales, equivalent to $3.75B. Other significant revenue streams include Opdivo and Orencia. Understanding this composition is critical for investors evaluating how BMY navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Bristol-Myers Squibb Co maintains a gross margin of 66.10%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 36.16%, while the net margin is 17.96%. These profitability ratios, combined with a Return on Equity (ROE) of 33.84%, provide a clear picture of how effectively BMY converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, BMY competes directly with industry leaders such as VRTX and SNY. With a market capitalization of $111.51B, it holds a significant position in the sector. When comparing efficiency, BMY's gross margin of 66.10% stands against VRTX's 86.52% and SNY's 68.80%. Such benchmarking helps identify whether Bristol-Myers Squibb Co is trading at a premium or discount relative to its financial performance.
